Hirotake Tsukamoto

Kyoto University — Japan

Immunology and Microbiology · Life Sciences

25h-index2.3kcitations171works0.72yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Immunotherapy and Immune Responses(60), Immune cells in cancer(43), Immune Cell Function and Interaction(35), Cancer Immunotherapy and Biomarkers(34), CAR-T cell therapy research(34)

Publications171 total

Figure S5 from Stromal Reprogramming through Dual PDGFRα/β Blockade Boosts the Efficacy of Anti–PD-1 Immunotherapy in Fibrotic Tumors
2025Open Access
Figure S3 from Stromal Reprogramming through Dual PDGFRα/β Blockade Boosts the Efficacy of Anti–PD-1 Immunotherapy in Fibrotic Tumors
2025Open Access
Figure S1 from Stromal Reprogramming through Dual PDGFRα/β Blockade Boosts the Efficacy of Anti–PD-1 Immunotherapy in Fibrotic Tumors
2025Open Access
Figure S6 from Stromal Reprogramming through Dual PDGFRα/β Blockade Boosts the Efficacy of Anti–PD-1 Immunotherapy in Fibrotic Tumors
2025Open Access
Figure S4 from Stromal Reprogramming through Dual PDGFRα/β Blockade Boosts the Efficacy of Anti–PD-1 Immunotherapy in Fibrotic Tumors
2025Open Access
Figure S9 from Stromal Reprogramming through Dual PDGFRα/β Blockade Boosts the Efficacy of Anti–PD-1 Immunotherapy in Fibrotic Tumors
2025Open Access
Figure S2 from Stromal Reprogramming through Dual PDGFRα/β Blockade Boosts the Efficacy of Anti–PD-1 Immunotherapy in Fibrotic Tumors
2025Open Access
Table S1, S2, S3, S4, S5, S6 Supplementary Figure legends from Stromal Reprogramming through Dual PDGFRα/β Blockade Boosts the Efficacy of Anti–PD-1 Immunotherapy in Fibrotic Tumors
2025Open Access
Figure S10 from Stromal Reprogramming through Dual PDGFRα/β Blockade Boosts the Efficacy of Anti–PD-1 Immunotherapy in Fibrotic Tumors
2025Open Access
Figure S8 from Stromal Reprogramming through Dual PDGFRα/β Blockade Boosts the Efficacy of Anti–PD-1 Immunotherapy in Fibrotic Tumors
2025Open Access
Figure S7 from Stromal Reprogramming through Dual PDGFRα/β Blockade Boosts the Efficacy of Anti–PD-1 Immunotherapy in Fibrotic Tumors
2025Open Access
Effect of organism aging on the development of anti-PD-(L)1 therapy-associated adverse events
Immunological Medicine·2025Open Access
Development status of the SMILE-3 balloon experiment
2025Open Access
Investigation of the intrinsic detector background for SMILE-3 balloon experiment
2025Open Access
ARNAX is an ideal adjuvant for COVID-19 vaccines to enhance antigen-specific CD4 <sup>+</sup> and CD8 <sup>+</sup> T-cell responses and neutralizing antibody induction
Journal of Virology·2025· 3 citedOpen Access
ICOS+CD4+ T cells define a high susceptibility to anti–PD-1 therapy–induced lung pathogenesis
JCI Insight·2025· 2 citedOpen Access
Anti-arthritic effects of polyunsaturated fatty acid–rich supplementation combined with selective soluble epoxide hydrolase inhibitors in a collagen-induced arthritis mouse model
Modern Rheumatology·2025· 1 citedOpen Access
Beneficial effects on T cells by photodynamic therapy with talaporfin enhance cancer immunotherapy
International Immunology·2025· 5 citedOpen Access
Celestial MeV gamma-ray observation using electron-tracking Compton camera loaded on long duration balloons (SMILE-3)
2024
Corrigendum to “Combined phospholipids adjuvant augments anti-tumor immune responses through activated tumor-associated dendritic cells” [Neoplasia 39 (2023), 100893]
Neoplasia·2024Open Access
page 1 of 9Next →

Frequent Co-authors

Yasuharu Nishimura(24), Satoru Senju(19), Hiroyuki Oshiumi(13), Atsushi Irie(11), Takahisa Kouwaki(8), Yoshihiro Komohara(8), Yusuke Tomita(8), Tokunori Ikeda(7), Akira Yuno(7), Masatoshi Hirayama(7), Masaaki Okamoto(6), Tetsuya Nakatsura(6), Yasushi Uemura(6), Satoshi Fukushima(5), Yoshihiro Yoshitake(5), Masanori Shinohara(5), Yoshimi Fukushima(4), Junji Yatsuda(4), Akinobu Hamada(4), Hirofumi Jono(4)